High-quality intermediates and equipment for the mAb and vaccine industry.
Monoclonal antibodies (mAbs) have revolutionized the pharmaceutical industry, transitioning from niche laboratory tools to the backbone of modern clinical therapy. As of 2024, the global mAb market is projected to exceed $200 billion, driven by the rising prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases.
The industrial status of mAbs is characterized by a shift toward high-concentration formulations and the integration of AI-driven cell line development. Leading manufacturers are now focusing on enhancing the "Experience, Expertise, Authoritativeness, and Trustworthiness" (E-E-A-T) of their supply chains to ensure patient safety and drug efficacy.
Staying ahead of the technological curve in the biologics sector.
Antibody-Drug Conjugates (ADCs) are combining the targeting precision of mAbs with the potency of cytotoxic drugs, creating "biological missiles" against tumors.
Shifting from batch processing to continuous bioprocessing to increase yield, reduce footprint, and lower costs for global suppliers.
As patent cliffs approach for blockbuster mAbs, the demand for high-quality biosimilar manufacturing has surged in emerging markets.
The industry leaders setting the gold standard for quality and innovation.
As a leading biochemical technology provider based in Hangzhou, China, we offer unique strategic advantages for global procurement:
Bridging the gap between lab research and clinical reality.
Global procurement needs for mAbs are not monolithic. In South East Asia, there is a massive demand for affordable biosimilars. In Europe and North America, the focus is on ultra-pure intermediates for novel drug discovery. Our role involves providing the essential chemical materials and technological transfer services that allow local companies to produce these life-saving drugs efficiently.
From providing Low Adsorption Surface Treated Glass Vials for stabilization to High-Precision Ceramic Plunger Pumps for sterile filling, we support every stage of the mAb lifecycle.
Hangzhou Jeci Biochem Technology Co., Ltd. is located in Hangzhou, Zhejiang Province. We are committed to sales of active pharmaceutical ingredients, pharmaceutical intermediates, nutritional products and food additives, cooperative R & D, custom manufacturing, sales and service as well as import of these kinds of materials.
In China, we have a strong collaborative R&D team, working in depth with new drug research institutes and multiple custom processing plants. We have very good domestic sales channels and have long-term relationships with domestic companies, including product applications, technology transfer, product supply, custom processing, and exclusive agents for multiple products in multiple regions. In addition, we also provide factory quality management system certification consulting services.
Drugs and intermediates are widely used in the following aspects (partial):
We are able to assemble and produce larger quantities of intermediates and provide some advanced, convenient manufacturing capabilities, including batch processing and customization. For the company's main product intermediates: We can maximize our advantages, meet the requirements of most customers and complete the task within the specified time limit.
Comprehensive support for pharmaceutical manufacturing.
SJ medical
